Atea Pharmaceuticals (AVIR) Q2 FY26 earnings call

Atea Pharmaceuticals reported positive Phase 3 C-Beyond trial results for its hepatitis C regimen, BAM-RZR, demonstrating non-inferiority to the standard of care and reinforcing its potential best-in-class profile for a complex patient population. The company is advancing its C-Forward trial and a novel hepatitis E program, while maintaining a solid financial position. Management believes BAM-RZR is uniquely positioned to expand the HCV market by addressing treatment barriers and capturing untreated patients, targeting a mid-2028 launch.